# Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

> **NCT04344795** · PHASE1 · COMPLETED · sponsor: **Tempest Therapeutics** · enrollment: 89 (actual)

## Conditions studied

- Solid Tumor
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Endometrial Cancer
- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma
- Solid Tumors With PIK3Ca Mutation

## Interventions

- **DRUG:** TPST-1495 twice daily
- **DRUG:** TPST-1495 once daily or on intermittent schedule
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04344795
- **Lead sponsor:** Tempest Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-06
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04344795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04344795, "Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04344795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*